Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free BFRIW Stock Alerts

Biofrontera (BFRIW) Competitors

Biofrontera logo
$0.02 -0.01 (-27.06%)
As of 05/14/2026 03:10 PM Eastern
Compare

BFRIW vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you buy Biofrontera stock or one of its competitors? MarketBeat compares Biofrontera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biofrontera include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does Biofrontera compare to Ainos?

Ainos (NASDAQ:AIMDW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Ainos and Ainos both had 1 articles in the media. Ainos' average media sentiment score of 1.89 beat Biofrontera's score of 1.87 indicating that Ainos is being referred to more favorably in the media.

Company Overall Sentiment
Ainos Very Positive
Biofrontera Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$124.16KN/AN/AN/AN/A
Biofrontera$41.71MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Biofrontera N/A N/A N/A

Summary

Ainos and Biofrontera tied by winning 1 of the 2 factors compared between the two stocks.

How does Biofrontera compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Alvotech had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Alvotech and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat Alvotech's score of 1.44 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
Biofrontera Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$586.32MN/AN/AN/AN/A
Biofrontera$41.71MN/AN/AN/AN/A

Summary

Alvotech beats Biofrontera on 2 of the 3 factors compared between the two stocks.

How does Biofrontera compare to Aravive?

Biofrontera (NASDAQ:BFRIW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$41.71MN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Biofrontera had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Aravive. Biofrontera's average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
Aravive Neutral

Summary

Biofrontera beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Biofrontera compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Biofrontera (NASDAQ:BFRIW) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Biofrontera N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Biofrontera$41.71MN/AN/AN/AN/A

In the previous week, Biofrontera had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Atlantic Coastal Acquisition Corp. II. Biofrontera's average media sentiment score of 1.87 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Biofrontera Very Positive

Summary

Biofrontera beats Atlantic Coastal Acquisition Corp. II on 3 of the 3 factors compared between the two stocks.

How does Biofrontera compare to Avidity Biosciences?

Biofrontera (NASDAQ:BFRIW) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Biofrontera has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Biofrontera's return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Avidity Biosciences -3,650.39%-44.92%-39.57%

Biofrontera has higher revenue and earnings than Avidity Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$41.71MN/AN/AN/AN/A
Avidity Biosciences$18.62MN/A-$322.30MN/AN/A

In the previous week, Avidity Biosciences had 2 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for Avidity Biosciences and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat Avidity Biosciences' score of 1.63 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
Avidity Biosciences Very Positive

Avidity Biosciences has a consensus price target of $69.42, suggesting a potential upside of 423.14%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Biofrontera.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biofrontera
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32

Summary

Biofrontera and Avidity Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Sign up to receive the latest news and ratings for BFRIW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRIW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BFRIW vs. The Competition

Export
MetricBiofronteraDrug Manufacturers IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.10B$6.34B$12.37B
Dividend YieldN/A2.97%2.80%5.35%
P/E RatioN/A5.2920.6625.63
Price / SalesN/A1,460.03547.7676.59
Price / CashN/A10.1843.2656.33
Price / BookN/A10.929.886.97
Net IncomeN/A$20.70B$3.55B$333.62M
7 Day PerformanceN/A0.73%1.69%1.09%
1 Month PerformanceN/A-2.47%0.48%3.08%
1 Year PerformanceN/A23.55%39.39%35.68%

Biofrontera Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BFRIW
Biofrontera
N/A$0.02
-27.1%		N/A-78.8%$0.00$41.71MN/A70
AIMDW
Ainos
N/A$0.11
+24.3%		N/A-1.4%$0.00$124.16KN/A40
ALVOW
Alvotech
N/A$0.28
+29.4%		N/A-85.9%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BFRIW) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel